Recently ICAM1 was reported to be an efficient target in CAR‐T treatment of thyroid cancers, confirmed the specific targeting of ICAM1 with limited distribution in normal tissues.[18] Furthermore, as shown in our studies, ICAM1 antibody also effectively suppresses PC cell migration in addition to the anticancer drug mertansine, DM1. Here, ICAM1 is linked to thyroid cancer.